Drugs Made In America Acquisition Corp. (DMAAU) Income from Continuing Operations (2025)
Drugs Made In America Acquisition's (DMAAU) quarterly Income from Continuing Operations came in at 212958.0 in Q4 2025, down 90.25% on a QoQ basis from 2184563.0 in Q3 2025.
Drugs Made In America Acquisition Corp. (DMAAU) Income from Continuing Operations (2025) Analysis & Trends
Drugs Made In America Acquisition (DMAAU) has 1 years of Income from Continuing Operations data on file, last reported at 212958.0 in Q4 2025.
- Quarterly Income from Continuing Operations changed N/A year-over-year to 212958.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 5940643.0 (changed N/A YoY) and the FY2025 annual result came in at 5940643.0, up 2222.83% from the prior year.
- Income from Continuing Operations eased to 212958.0 in Q4 2025, from 2184563.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 2288579.0 in Q2 2025 to a low of 212958.0 in Q4 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 212,958.00 |
| Sep 30, 2025 | 2.18 Mn |
| Jun 30, 2025 | 2.29 Mn |
| Mar 31, 2025 | 1.25 Mn |